Is UPL's worst phase finally behind it?

Summary: UPL has been through one of the toughest phases in its history. Debt pressures, margin stress, shaken confidence, you name it. Now, with balance sheets healing, is the worst truly behind it? Here’s what has changed, what hasn’t, and whether this recovery has real legs.

The market has begun to look kindly upon UPL again. The stock is now trading close to its all-time high, which is striking for a business whose past two years have been among its most difficult. UPL, once a beloved chemical bet, saw its earnings weaken sharply, margins compress, with soaring debt and credit rating downgrades.

But there’s a growing belief now that the company has moved past its most fragile phase. Here’s a look at what went wrong in the past and how the business is winning back market favour:

One acquisition that changed it all

UPL built its place among the global agrochemical elites steadily over decades through a mix of organic expansion and acquisitions. This helped it evolve from an Indian generics manufacturer into one of the world’s largest crop protection companies with operations across more than 130 countries.

One defining step in this journey was the acquisition of Arysta LifeScience in FY19. The deal lifted UPL’s business profile, adding branded formulations, deeper farmer relationships and a strong presence in Latin America, which is now its largest market with a 38 per cent revenue share for the first half of FY26.

Strategically, the acquisition made sense. Financially, it changed UPL’s risk profile overnight and increased leverage to astonishing levels. UPL’s debt-to-equity ratio rose sharply from about 0.7 times in FY18 to nearly 2 times in FY19, while gross debt levels increased more than fourfold. At the time, the higher leverage appeared manageable given stable industry conditions and strong operating cash flows. However, the margin for error had narrowed.

During the Covid years, industry-wide supply disruptions temporarily masked these risks. Pricing was better, margins saw expansion and cash flows remained supportive. But this was transitory.

How operating stress exposed balance-sheet fragility

Once global supply chains normalised, Chinese manufacturers returned aggressively with excess supply. Active ingredient prices fell sharply. At the same time, distributors across markets began to destock after over-ordering during the disruption phase.

UPL’s pivotal Latin America business was the worst hit given it was heavily driven by distributors. Weak farm incomes, lower crop prices and intense price competition combined to hurt volumes, stretch receivables and inflate inventories. As the company turned losses, leverage metrics worsened further and investor focus shifted away from growth to the sustainability of the balance sheet.

Next came governance complexity and credit downgrades

Operating stress soon translated into investor unease. UPL’s complex structure, with a large number of overseas subsidiaries and associates, came under scrutiny. Losses in certain Latin American entities and the opacity of some joint ventures raised questions around governance and oversight.

Credit rating agencies responded by downgrading UPL’s outlook to “negative”. This mattered. For a globally leveraged business, a negative outlook increases funding costs and heightens refinancing risk. By FY24, UPL’s narrative had shifted decisively from expansion to survival.

The reset: repairing the balance sheet

What has changed since then is not a sudden surge in demand but a clear financial reset.

In December 2024, UPL undertook a rights issue aggregating to about Rs 3,380 crore, executed in phases and fully subscribed. While dilutive in the short term, the capital raise directly addressed leverage concerns and strengthened liquidity. Alongside this, the company tightened working-capital controls, reduced inventories and improved receivable collections. Debt repayments and the redemption of perpetual instruments further aided deleveraging.

The results are visible:

• Net debt-to-equity improved to around 0.6 times, from levels close to 0.9 times a year earlier
• Net debt-to-EBITDA declined to around 2.7 times, from over 5 times during the stress phase

These improvements have led credit rating agencies to revise UPL’s outlook from “negative” to “stable”, significantly lowering perceived solvency risk.

Market turns favourable

The easing in balance sheet stress has been accompanied by better market conditions. Channel inventory levels, particularly in Latin America, have normalised after nearly two years of destocking. Ordering patterns are no longer erratic, even if demand remains measured. Margins have improved meaningfully, driven by better product mix and lower input costs.

Growth has also become broader, with India, North America, seeds and specialty chemicals contributing, while Latin America has stabilised rather than deteriorating further.

Guidance reflects confidence

Management commentary has turned noticeably more confident. As of Q2 FY26, UPL has guided for:

• Mid-single-digit revenue growth
• Sustained improvement in EBITDA margins
• Continued focus on reducing net debt through cash generation

The guidance is conservative and not aggressive, but after the turbulence of the past two years, credibility matters more than ambition.

What the recovery means for investors

The stock’s return to record levels is not a bet on peak-cycle profitability. Instead, it reflects a reassessment of risk. Three changes that stand out are: Balance sheet risk has reduced materially, operating performance has stabilised with visible margin recovery and the probability of a prolonged liquidity or solvency scare has fallen sharply.

For a leveraged global business, this change in risk perception alone can drive a meaningful rerating. If UPL sustains this trajectory, the stock will look interesting again given current valuation is also comfortable.

However, market conditions remain an ever-present risk, especially since the company’s debt levels, despite meaningful improvement, are not low. Any deal or expansion that increases leverage could expose the company severely to market vulnerabilities again. Both management discretion and how the market behaves remain crucial variables in the ongoing recovery.

Looking for businesses that can endure cycles and emerge stronger?

Stories like UPL’s are a reminder that market cycles test even the strongest businesses. What matters in the long run is the ability to survive stress, repair balance sheets and emerge stronger. At Value Research Stock Advisor, we focus on finding exactly such companies. Join us and find stocks that are capable of keeping setbacks behind them to create long-lasting wealth.

Try Stock Advisor

Also read: Solid earnings, muted prices: What is the market signalling?

This article was originally published on January 04, 2026.